Information  X 
Enter a valid email address

Syncona Limited (SYNC)

  Print      Mail a friend

Thursday 27 June, 2019

Syncona Limited

Publication of Annual Report and Notice of AGM

RNS Number : 6764D
Syncona Limited
27 June 2019

Syncona Limited

Publication of 2019 Annual Report and Notice of Annual General Meeting

27 June 2019

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces that it has published its Annual Report and Accounts for the year ended 31 March 2019 ("2019 Annual Report"). In addition, Syncona has published its Notice of Annual General Meeting 2019 and a circular relating to the 2019 Dividend.

In compliance with Listing Rule 9.6.1, these documents have today been submitted to the National Storage Mechanism and will shortly be available for inspection at

Copies of these documents, together with the Form of Proxy for use in connection with the 2019 Annual General Meeting, Charitable Allocation Form and Cash Election Form, are available electronically on Syncona's website at Printed copies of these documents are also being posted to shareholders where requested.

Syncona's Annual General Meeting will be held at 10:30am on 30 July 2019 at the offices of Citco Fund Services (Guernsey) Limited, Arnold House, St Julian's Avenue, St Peter Port, Guernsey, GY1 3RD.




Syncona Ltd

Siobhan Weaver / Annabel Clay  

Tel : +44 (0) 20 3981 7940


FTI Consulting

Brett Pollard / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at:  

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t